Upwards arrow: Go back to top

Join us on LinkedIn for the latest news.

News & Press

Learn more about recent advances in biotech, health tech and our work.

Scripta Therapeutics: AI-Powered Drug Discovery for Neurodegenerative DiseasesScripta Therapeutics: AI-Powered Drug Discovery for Neurodegenerative Diseases
18.9.2026
Scripta Therapeutics: AI-Powered Drug Discovery for Neurodegenerative Diseases
Therini Bio: Fibrin-Targeted Therapies for Neurological and Retinal DiseasesTherini Bio: Fibrin-Targeted Therapies for Neurological and Retinal Diseases
18.9.2026
Therini Bio: Fibrin-Targeted Therapies for Neurological and Retinal Diseases
BioNYRA Pharma: Next-Generation Antibody Therapies for Immune-Mediated Inflammatory DiseasesBioNYRA Pharma: Next-Generation Antibody Therapies for Immune-Mediated Inflammatory Diseases
18.9.2026
BioNYRA Pharma: Next-Generation Antibody Therapies for Immune-Mediated Inflammatory Diseases
Auron Announces First Patient Dosed in Phase 1 Clinical Trial of AUTX-703 in Advanced Hematologic MalignanciesAuron Announces First Patient Dosed in Phase 1 Clinical Trial of AUTX-703 in Advanced Hematologic Malignancies
29.5.2025
Auron Announces First Patient Dosed in Phase 1 Clinical Trial of AUTX-703 in Advanced Hematologic Malignancies
Therini Bio Raises Additional $39M Series A Financing to Advance Clinical Development of Neurodegenerative Disease PipelineTherini Bio Raises Additional $39M Series A Financing to Advance Clinical Development of Neurodegenerative Disease Pipeline
14.5.2025
Therini Bio Raises Additional $39M Series A Financing to Advance Clinical Development of Neurodegenerative Disease Pipeline
HAYA Therapeutics Raises $65 Million in Series A Funding to Deliver Precision RNA-Guided Medicines for Chronic and Age-Related DiseasesHAYA Therapeutics Raises $65 Million in Series A Funding to Deliver Precision RNA-Guided Medicines for Chronic and Age-Related Diseases
8.5.2025
HAYA Therapeutics Raises $65 Million in Series A Funding to Deliver Precision RNA-Guided Medicines for Chronic and Age-Related Diseases
Auron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous LeukemiaAuron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous Leukemia
24.2.2025
Auron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous Leukemia
Auron Therapeutics secures FDA clearance & $27M Series B to advance precision oncologyAuron Therapeutics secures FDA clearance & $27M Series B to advance precision oncology
4.2.2025
Auron Therapeutics secures FDA clearance & $27M Series B to advance precision oncology